印 琳,劉 芳,郭長(zhǎng)城,王 瓊,楊 杰,潘 科,潘 晨,熊 妍,陳穎婷,方 文,陳崢宏
胃黏膜組織中惡臭假單胞菌臨床意義的探討
印 琳1,2,劉 芳2,郭長(zhǎng)城2,王 瓊2,楊 杰3,潘 科4,潘 晨3,熊 妍5,陳穎婷3,方 文1,陳崢宏2
目的 探索惡臭假單胞菌在幽門螺桿菌感染相關(guān)胃腸疾病中的意義。方法采集14C尿素呼氣試驗(yàn)陽(yáng)性患者病變胃黏膜354例,進(jìn)行細(xì)菌的分離培養(yǎng)。根據(jù)菌落形態(tài)、革蘭染色、尿素酶試驗(yàn)及幽門螺桿菌特異性16S rRNA基因片段的PCR進(jìn)行幽門螺桿菌的鑒定,同時(shí)提取胃黏膜組織DNA,通過(guò)幽門螺桿菌特異性PCR進(jìn)行快速診斷。將非幽門螺桿菌轉(zhuǎn)種于營(yíng)養(yǎng)瓊脂培養(yǎng)基,進(jìn)行快速尿素酶試驗(yàn)。尿素酶陽(yáng)性的非幽門螺桿菌染色體DNA利用細(xì)菌16S rRNA基因通用引物進(jìn)行PCR擴(kuò)增、測(cè)序及序列比對(duì)。使用全自動(dòng)細(xì)菌鑒定儀對(duì)經(jīng)測(cè)序比對(duì)為惡臭假單胞菌的菌株進(jìn)行鑒定。采用K-B紙片擴(kuò)散法進(jìn)行藥物敏感性試驗(yàn)。結(jié)果從354例樣本中分離出革蘭陰性、尿素酶陽(yáng)性的惡臭假單胞菌10株,經(jīng)16S rRNA基因測(cè)序和序列比對(duì),與GenBank中惡臭假單胞菌的相似性≥98%。10株惡臭假單胞菌的胃黏膜標(biāo)本中,6例標(biāo)本幽門螺桿菌特異性PCR為陽(yáng)性,4例為陰性。傳代存活的7株惡臭假單胞菌的K-B法藥物敏感試驗(yàn)顯示對(duì)左氧氟沙星均敏感,1株對(duì)四環(huán)素敏感, 5株對(duì)阿莫西林耐藥,6株對(duì)克拉霉素耐藥,7株對(duì)甲硝唑、氨芐青霉素均耐藥。7株菌經(jīng)全自動(dòng)細(xì)菌生化鑒定儀鑒定結(jié)果均為惡臭假單胞菌。結(jié)論病變胃黏膜中分離出尿素酶陽(yáng)性且對(duì)治療幽門螺桿菌感染的多種抗生素耐藥;可能造成臨床上14C-尿素呼氣試驗(yàn)假陽(yáng)性,并繼發(fā)感染影響胃腸疾病的進(jìn)展。
惡臭假單胞菌;培養(yǎng);尿素酶;16S rRNA;耐藥性
惡臭假單胞菌(Pseudomonasputida)是一種革蘭陰性桿菌,有些菌株為卵圓形,單端叢毛菌,運(yùn)動(dòng)活潑。惡臭假單胞菌為魚的一種致病菌,常從腐敗的魚中檢出,可作為人類咽部的正常菌群,是人類少見(jiàn)的條件致病菌,偶從人類尿道感染、皮膚感染和骨髓炎標(biāo)本中分離出[1]。
Yoshino Y等報(bào)道,惡臭假單胞菌是一種低毒機(jī)會(huì)性致病原,原發(fā)性感染可致免疫功能低下和使用醫(yī)療設(shè)備(或?qū)蚬?病人的院內(nèi)感染[2-3]。Souza Dias MB等報(bào)道,因輸血或輸液感染暴發(fā)惡臭假單胞菌菌血癥[4]。研究報(bào)道肺炎、扁桃體炎、導(dǎo)管相關(guān)性血源性感染、急性膽囊炎和膽管炎、血栓性靜脈炎和皮膚軟組織炎癥(SSTI)等可致惡臭假單胞菌菌血癥[5-7],甚至引發(fā)多器官衰竭并導(dǎo)致死亡[5]。
我們?cè)趯?duì)胃、十二指腸患者病變胃黏膜進(jìn)行幽門螺桿菌(H.pylori)分離培養(yǎng)時(shí)發(fā)現(xiàn),病變胃黏膜中存在對(duì)治療幽門螺桿菌的抗生素耐藥,并且是尿素酶陽(yáng)性的非幽門螺桿菌,經(jīng)細(xì)菌16S rRNA基因的PCR及測(cè)序確定為惡臭假單胞菌,現(xiàn)報(bào)道如下。
1.1 材料
1.1.1 樣本來(lái)源 病變胃黏膜來(lái)源于2015年3月至2015年12月,因上消化道不適癥狀就診于貴州醫(yī)科大學(xué)附屬醫(yī)院、貴州醫(yī)科大學(xué)附屬白云醫(yī)院、貴陽(yáng)市兒童醫(yī)院、黔南布依族苗族自治州人民醫(yī)院內(nèi)鏡室,14C-尿素呼氣試驗(yàn)陽(yáng)性、胃鏡檢查有病變的患者354例?;颊咝g(shù)前6~8 h禁飲禁食,手術(shù)用的胃鏡經(jīng)過(guò)嚴(yán)格洗滌消毒處理。無(wú)痛胃鏡狀態(tài)下,對(duì)于內(nèi)窺鏡下觀察有病變的胃黏膜,使用一次性活檢鉗采集病灶旁組織1塊。標(biāo)本采集取得病人知情同意,實(shí)驗(yàn)方案通過(guò)貴州醫(yī)科大學(xué)附屬醫(yī)院醫(yī)學(xué)倫理委員會(huì)審查。
1.1.2 培養(yǎng)基 營(yíng)養(yǎng)瓊脂培養(yǎng)基(上海博微生物科技有限公司);MH瓊脂培養(yǎng)基(杭州濱和微生物試劑有限公司);選擇性培養(yǎng)基:MH血瓊脂培養(yǎng)基(含10%無(wú)菌脫纖維羊血和幽門螺桿菌選擇性添加劑[英國(guó),OXOID,含萬(wàn)古霉素5.0 mg,頭孢磺啶2.5 mg,甲氧芐氨嘧啶2.5 mg,兩性霉素B 2.5 mg])。
1.1.3 其他材料:微需氧產(chǎn)氣袋(日本,三菱化學(xué)株式會(huì)社)、快速尿素酶試紙(珠海市克迪科技開(kāi)發(fā)有限公司)、革蘭染色液(青島海博生物技術(shù)有限公司)、細(xì)菌基因組DNA提取試劑盒(生工生物工程上海股份有限公司)、血液組織細(xì)胞基因組DNA提取試劑盒和DNA Marker Ⅶ(北京天根生化科技有限公司)、細(xì)菌16S rRNA基因通用引物(27F;1492R)和幽門螺桿菌16S rRNA基因特異性引物(上海英駿生物技術(shù)有限公司合成)。藥敏紙片(購(gòu)自杭州濱和微生物試劑有限公司):阿莫西林;克拉霉素;甲硝唑;左氧氟沙星;四環(huán)素;氨芐青霉素。高速臺(tái)式離心機(jī)TGL-16B(上海安亭科學(xué)儀器廠);數(shù)顯隔水式培養(yǎng)箱303AB-4型(武漢精華科教儀器有限公司);PCR擴(kuò)增儀(杭州晶格科學(xué)儀器有限公司)。貴州省人民醫(yī)院中心實(shí)驗(yàn)室BD PhoenixTM-100全自動(dòng)細(xì)菌鑒定/藥敏系統(tǒng)。
1.2 方法
1.2.1 惡臭假單胞菌的分離和鑒定 354例疑為幽門螺桿菌感染的胃黏膜樣本參考文獻(xiàn)[8]進(jìn)行幽門螺桿菌的分離培養(yǎng),根據(jù)菌落形態(tài)、革蘭染色、尿素酶試驗(yàn)以及幽門螺桿菌特異性16S rRNA基因片段的PCR進(jìn)行鑒定,區(qū)分幽門螺桿菌和非幽門螺桿菌。將非幽門螺桿菌轉(zhuǎn)種于營(yíng)養(yǎng)瓊脂培養(yǎng)基,37 ℃需養(yǎng)培養(yǎng)18~24 h后,以尿素酶試紙進(jìn)行快速尿素酶試驗(yàn)。
取尿素酶陽(yáng)性的細(xì)菌單菌落以細(xì)菌基因組DNA提取試劑盒提取細(xì)菌染色體DNA,利用細(xì)菌16S rRNA基因的通用引物(27F;1492R)[9]進(jìn)行PCR擴(kuò)增,純化的PCR產(chǎn)物由生工生物工程上海有限公司(Sangon Biotech)采用Sanger法進(jìn)行測(cè)序,測(cè)序結(jié)果在GenBank(https://www.ncbi.nlm.nih.gov)進(jìn)行序列比對(duì),以鑒定菌種。
1.2.2 病變組織中幽門螺桿菌16S rRNA基因片段的PCR擴(kuò)增:將100 μL患者病變黏膜組織懸液用DNA提取試劑盒提取組織及組織中細(xì)菌的DNA,通過(guò)幽門螺桿菌特異性16S rRNA 基因片段PCR進(jìn)行幽門螺桿菌感染的快速診斷[10]。
1.2.3 藥物敏感性試驗(yàn) 參照WHO推薦的K-B紙片擴(kuò)散法,測(cè)定經(jīng)16S rRNA基因序列比對(duì)鑒定為惡臭假單胞菌的單菌落培養(yǎng)物對(duì)甲硝唑(5 μg/片)、氨芐青霉素(10 μg/片)、阿莫西林(10 μg/片)、克拉霉素(15 μg/片)、左氧氟沙星(5 μg/片)、四環(huán)素(30 μg/片)6種藥物的藥物敏感性。0.85%生理鹽水制備0.5麥?zhǔn)蠁挝痪鷳乙?,吸?00 μL菌懸液均勻涂布于MH平板表面,無(wú)菌操作將藥敏紙片貼于瓊脂平板上。37 ℃培養(yǎng)18~24 h后測(cè)量藥敏紙片抑菌圈直徑。藥敏試驗(yàn)依據(jù)美國(guó)CLSI《抗菌藥物敏感性試驗(yàn)指南》標(biāo)準(zhǔn)進(jìn)行結(jié)果判斷[11]。
1.2.4 惡臭假單胞菌的全自動(dòng)生化鑒定 將復(fù)蘇成功的經(jīng)NCBI序列比對(duì)為惡臭假單胞菌的7株菌送至貴州省人民醫(yī)院中心實(shí)驗(yàn)室,使用BD PhoenixTM-100全自動(dòng)細(xì)菌鑒定/藥敏系統(tǒng)進(jìn)行細(xì)菌生化鑒定。
2.1 惡臭假單胞菌的分離和鑒定 從354例胃黏膜樣本中共分離獲得10株惡臭假單胞菌,為革蘭陰性桿菌(或球桿菌),尿素酶試驗(yàn)陽(yáng)性。以細(xì)菌16S rRNA基因的通用引物進(jìn)行PCR,10株菌的擴(kuò)增產(chǎn)物均為1 465 bp(見(jiàn)圖1),經(jīng)測(cè)序及序列比對(duì),與數(shù)據(jù)庫(kù)中惡臭假單胞菌16S rRNA基因序列的一致性最高,均高于98%。該10例樣本幽門螺桿菌分離培養(yǎng)結(jié)果及臨床診斷見(jiàn)表1。
M: DNA markerⅦ;泳道1-10:10株分離自胃黏膜的惡臭假單胞菌PCR產(chǎn)物;泳道11: 陰性對(duì)照(ddH2O);泳道12:陽(yáng)性對(duì)照(H.pylori NCTC 11637)M: DNA Marker Ⅶ; Lane 1-10: PCR products of 10 strains Pseudomonas putida isolated from gastric mucosa tissue; Lane 11: Negative control (ddH2O); Lane 12: Positive control (H. pylori NCTC 11637).圖1 10株惡臭假單胞菌利用細(xì)菌16S rRNA基因通用引物PCR擴(kuò)增結(jié)果Fig.1 PCR amplification of 10 strains Pseudomonas putida by general primers of bacterial 16S rRNA gene
2.2 胃黏膜組織進(jìn)行幽門螺桿菌特異性PCR快速診斷結(jié)果 10例分離出惡臭假單胞菌的胃黏膜標(biāo)本均未培養(yǎng)出幽門螺桿菌,有6例組織標(biāo)本的幽門螺桿菌特異性PCR結(jié)果為陽(yáng)性,4例標(biāo)本為陰性,見(jiàn)表1。
2.3 惡臭假單胞菌的K-B法藥敏檢測(cè)結(jié)果 由于傳代保種中死亡,有3株菌未做藥敏試驗(yàn),存活的7株菌對(duì)左氧氟沙星均敏感,對(duì)四環(huán)素1株敏感,但對(duì)甲硝唑、氨芐青霉素均耐藥,對(duì)阿莫西林、克拉霉素多為耐藥,見(jiàn)表2。
2.4 全自動(dòng)細(xì)菌生化鑒定及藥敏試驗(yàn)結(jié)果 7株傳代存活的菌株經(jīng)BD PhoenixTM-100全自動(dòng)細(xì)菌鑒定儀鑒定為惡臭假單胞菌。細(xì)菌生化反應(yīng)見(jiàn)表3。
低胃酸(pH<4)通常被認(rèn)為是一個(gè)防止胃內(nèi)微生物過(guò)度生長(zhǎng)的有效殺菌屏障[12],并且胃內(nèi)膽汁酸的反流,較厚的粘液層和胃的蠕動(dòng)等因素都不適宜于細(xì)菌的定植。同時(shí),唾液和食物中由口腔內(nèi)乳酸桿菌轉(zhuǎn)化硝酸鹽形成的亞硝酸鹽在胃液作用下產(chǎn)生的一氧化氮,也參與上消化道的先天性防御。因此過(guò)去長(zhǎng)期認(rèn)為“胃是無(wú)菌器官”[13-14]。直至1982年,Barry Marshall 和Robin Warren發(fā)現(xiàn)幽門螺桿菌,并指出幽門螺桿菌與胃炎、胃潰瘍、胃癌、胃黏膜相關(guān)性淋巴樣組織淋巴瘤的相關(guān)性(MALT)[15],徹底顛覆胃內(nèi)無(wú)菌的傳統(tǒng)觀點(diǎn)。
表1 10株惡臭假單胞菌培養(yǎng)及鑒定一般情況
Tab.1 General culture and identification information of 10 strains P. putida
標(biāo)本編號(hào)Specimenserialnumber革蘭染色Gramsstaining尿素酶試驗(yàn)Ureasetest胃黏膜組織的H.pylori特異性PCRH.pylorispecificPCRofgastricmucusatissueH.pylori培養(yǎng)結(jié)果H.pyloriculture臨床診斷ClinicaldiagnosisG16G-球桿菌G-coccobacillus+--慢性非萎縮性胃炎Chronicnon?atrophicgastritisG45G-球桿菌G-coccobacillus++-胃角潰瘍A1-H1期;慢性非萎縮性胃炎Gastricangleulcer(A1-H1phases);Chronicnon?atrophicgastritiswithgas?tricantrumerosionG47G-短桿菌G-bacillusbrevis+--慢性非萎縮性胃炎伴幽門前區(qū)淺潰瘍A2期Chronicnon?atrophicgastritiswithprepyloriculcer(A2phase)G79G-球桿菌G-coccobacillus+--慢性非萎縮性胃炎Chronicnon?atrophicgastritisG88G-球桿菌G-coccobacillus++-胃竇潰瘍H1期;慢性非萎縮性胃炎Gastricantrumulcer(H1phase);Chronicnon?atrophicgastritisD210G-短桿菌G-bacillusbrevis++-慢性胃炎ChronicgastritisD217G-短桿菌G-bacillusbrevis++-慢性胃炎;十二指腸息肉Chronicgastritis;DuodenalpolypsD228G-短桿菌G-bacillusbrevis++-全胃炎AllgastritisD230G-短桿菌G-bacillusbrevis++-胃多發(fā)性潰瘍MultiplegastriculcerD256G-短桿菌G-bacillusbrevis+--慢性胃炎Chronicgastritis
注:“+”為陽(yáng)性,“-”為陰性
Note:"+"is positive; "-"is negative
表2 7株惡臭假單胞菌K-B法藥敏檢測(cè)結(jié)果Tab.2 Antibiotic susceptibility of 7 strains of P. putida
藥物名稱Nameofantibiotics菌株數(shù)(n)No.ofstrains敏感株(n)No.ofsusceptiblestrains中介(n)No.ofintermediatestrains耐藥株(n)No.ofresistantstrains甲硝唑metronidazole7007氨芐青霉素Ampicillin7007阿莫西林amoxicillin7025克拉霉素clarithromycin7016四環(huán)素tetracycline7160左氧氟沙星levofloxacin7700
表3 7株非幽門螺桿菌的生化鑒定結(jié)果Tab.3 Biochemical identification results of 7 non-H.pylori strains
Oxidase+L.Gamma.Glutamyl.p.Nitroanilid+Arginine?Arginine-L.Proline.p.Nitroanilide+Glycine?Proline-p.Nitrophenyl.B.D.Glucoside-Glycine-Bis[p.Nitrophenyl]Phosphate-N?Glutaryl?Glycine.Arginine-B.D.Allose-L?Arginine-B.Gentiobiose-L?GlutamicAcid-Dextrose+L?Leucine+D.Fructose-L?Phenylalanine+D.Galactose-L?Proline-D.GluconicAcid-L?PyroglutamicAcid-D.Melibiose-L?Tryptophane-D.Sorbitol-Lysine.Alanine-D.Sucrose-Acetate-GalacturonicAcid-Adonitol-L.Arabinose-Citrate-L.Rhamnose-Colistin-Mehyl.B.Glucoside-D.Mannitol-Maltulose-KetoglutaricAcid(A)-N.Acetyl.Galactosamine-Malonate-N.Acetyl.Glucosamine-PolymyxinB-Ornithine-TiglicAcid-Urea-4?Methylumbelliferyl-Esculin-
注:“+”為陽(yáng)性,“-”為陰性
Note:"+"is positive; "-"is negative
近年來(lái),隨著分子生物學(xué)和細(xì)菌16S rRNA基因鑒定技術(shù)的發(fā)展并用于胃微生態(tài)的研究,出現(xiàn)較新的關(guān)于胃內(nèi)菌群以及影響胃內(nèi)菌群因素的相關(guān)報(bào)道。Aviles-Jimenez等研究發(fā)現(xiàn)人體胃有一個(gè)復(fù)雜的微生物群定植,主要包括變形桿菌屬、放線菌屬、厚壁菌屬、梭形桿菌屬,顯示了與口腔和食管內(nèi)微生物群的顯著區(qū)別[16]。Hu Y等使用細(xì)菌分離培養(yǎng)和基質(zhì)輔助激光解吸電離飛行時(shí)間質(zhì)譜(MALDI-TOF MS)也從胃內(nèi)分離鑒定出201株非幽門螺桿菌[17]。Osaki等報(bào)道發(fā)現(xiàn),長(zhǎng)期幽門螺桿菌感染能改變蒙古沙鼠胃內(nèi)微生物的細(xì)菌組成[18]。Nardone G等發(fā)現(xiàn),長(zhǎng)期使用PPIs和H2受體拮抗劑,能影響胃內(nèi)微生態(tài)的組成,當(dāng)胃內(nèi)pH>3.8時(shí)可出現(xiàn)細(xì)菌過(guò)度增長(zhǎng)[14]。
我們?cè)趯?duì)臨床病變胃黏膜進(jìn)行幽門螺桿菌分離培養(yǎng)的工作中發(fā)現(xiàn),即使是在含有萬(wàn)古霉素、頭孢磺啶、甲氧芐氨嘧啶和兩性霉素B的幽門螺桿菌選擇性培養(yǎng)基中仍然有非幽門螺桿菌的生長(zhǎng),其中不乏尿素酶陽(yáng)性的非幽門螺桿菌。本次研究在354例疑為幽門螺桿菌感染者的胃黏膜組織中分離獲得的非幽門螺桿菌,經(jīng)16S rRNA基因測(cè)序和NCBI數(shù)據(jù)庫(kù)比對(duì),10株菌的序列比對(duì)結(jié)果與惡臭假單胞菌一致性最高。在傳代保種和菌種復(fù)蘇過(guò)程中,3株菌死亡,傳代存活的7株菌經(jīng)全自動(dòng)細(xì)菌生化鑒定儀鑒定為惡臭假單胞菌。
分離培養(yǎng)出惡臭假單胞菌的10例病人樣本均未培養(yǎng)出幽門螺桿菌,但有6例組織為幽門螺桿菌特異性PCR陽(yáng)性,這6例PCR陽(yáng)性但培養(yǎng)陰性的原因可能為黏膜中幽門螺桿菌數(shù)量較少,或者在運(yùn)送過(guò)程中死亡,或者因患者曾經(jīng)使用抗生素治療以及惡臭假單胞菌在培養(yǎng)基上競(jìng)爭(zhēng)性生長(zhǎng)抑制了幽門螺桿菌的生長(zhǎng)和繁殖。另4株分離得到惡臭假單胞菌的胃黏膜樣本無(wú)論培養(yǎng)還是靈敏度較高的組織PCR均未檢測(cè)到幽門螺桿菌,但這些患者的14C-尿素呼氣試驗(yàn)卻為陽(yáng)性,且胃鏡檢查也有黏膜病變,提示胃內(nèi)存在尿素酶陽(yáng)性的非幽門螺桿菌。Abreu MT等報(bào)道,胃內(nèi)微生態(tài)群中產(chǎn)尿素酶的細(xì)菌除了幽門螺桿菌,還有奇異變形桿菌、肺炎克雷伯菌、金黃色釀膿葡萄球菌、頭狀葡萄球菌和微球菌屬可致14C-尿素呼氣試驗(yàn)假陽(yáng)性結(jié)果[19]。部分惡臭假單胞菌也具有尿素酶活性[20],可分解尿素產(chǎn)氨,氨中和部分胃酸,造成局部低酸環(huán)境,有利于細(xì)菌在胃內(nèi)的生存。本實(shí)驗(yàn)分離得到的惡臭假單胞菌經(jīng)尿素酶試紙快速檢測(cè)為陽(yáng)性,但臨床生化鑒定卻為陰性,原因?yàn)樵摼N存在尿素水解試驗(yàn)結(jié)果不確定的菌株[20]。臨床上,部分病人進(jìn)行胃鏡檢查前曾有過(guò)抑酸劑和抗生素(如阿莫西林、甲硝唑、克拉霉素)的服用史。經(jīng)過(guò)治療,胃內(nèi)幽門螺桿菌的生長(zhǎng)受到抑制,但胃生理和生態(tài)環(huán)境改變的胃黏膜可能繼發(fā)一些非幽門螺桿菌的生長(zhǎng),特別是對(duì)治療幽門螺桿菌感染用的抗生素耐藥的細(xì)菌。本次研究從患者胃黏膜分離的7株惡臭假單胞菌均對(duì)甲硝唑、氨芐青霉素耐藥,多數(shù)菌株對(duì)阿莫西林、克拉霉素耐藥,然而這些抗生素正是目前常用于治療幽門螺桿菌感染的抗菌藥物。
致謝:感謝貴州醫(yī)科大學(xué)消化內(nèi)鏡中心許良壁主任及全體工作人員的支持與幫助;感謝貴州醫(yī)科大學(xué)附屬白云醫(yī)院內(nèi)鏡室的支持與幫助;感謝貴陽(yáng)市兒童醫(yī)院內(nèi)鏡室的支持與幫助;感謝黔南布依族苗族自治州人民醫(yī)院的支持與幫助!
[1] Li J, Zou MX, Wang HC, et al. Mechanism of drug resistance of a strain of extensively drug resistantPseudomonasputida[J]. Chin J Microecol, 2016, 28(1): 1-5. DOI: 10.13381/j.cnki.cjm.201601001 (in Chinese)
李軍,鄒明祥,王海晨,等.一株廣泛耐藥惡臭假單胞菌耐藥機(jī)制研究[J].中國(guó)微生態(tài)學(xué)雜志,2016,28(1):1-5.
[2] Liu YM, Liu K, Yu XM, et al. Identification and control of aPseudomonasspp. (P.fulvaandP.putida) bloodstream infection outbreak in a teaching hospital in Beijing, China[J]. Int J Infect Dis, 2014, 23: 105-108. DOI: 10.1016/j.ijid.2014.02.013
[3] Yoshino Y, Kitazawa T, Kamimura M, et al.Pseudomonasputidabacteremia in adult patients: five case reports and a review of the literature[J]. J Infect Chemother, 2011, 17 (2): 278-282. DOI: 10.1007/s10156-010-0114-0
[4] Souza Dias MB, Habert AB, Borrasca V, et al. Salvage of long-term central venous catheters during an outbreak ofPseudomonasputidaandStenotrophomonasmaltophiliainfections associated with contaminated heparin catheter-lock solution[J]. Infect Control Hosp Epidemiol, 2008, 29(2): 125-130. DOI: 10.1086/526440
[5] Thomas BS, Okamoto K, Bankowski MJ, et al. A lethal case ofPseudomonasputidabacteremia due to soft tissue infection[J]. Infect Dis Clin Pract (Baltim Md), 2013, 21 (3): 147-213. DOI: 10.1097/IPC.0b013e318276956b
[6] Carpenter RJ, Hartzell JD, Forsberg JA, et al.Pseudomonasputidawar wound infection in a US Marine: a case report and review of the literature[J]. J Infect, 2008, 56(4): 234-240. DOI: 10.1016/j.jinf.2008.01.004
[7] Chen CH, Hsiu RH, Liu CE, et al.Pseudomonasputidabacteremia due to soft tissue infection contracted in a flooded area of central Taiwan: a case report[J]. J Microbiol Immunol Infect, 2005, 38(4): 293-295.
[8] Wang Q, Yang J, Pan K, et al. Effect of different transport conditions and media onHelicobacterpyloriisolation[J]. World Chin J Digestol, 2016, 24(8): 1241-1246. DOI: 10.11569/wcjd.v24.i8.1241 (in Chinese)
王瓊, 楊杰, 潘科, 等. 幽門螺桿菌不同運(yùn)送條件及培養(yǎng)基分離效果的比較[J]. 世界華人消化雜志, 2016, 24 (8) : 1241-1246.
[9] Wei GF, Lu HF, Zhou ZH, et al. The microbial community in the feces of the giant panda (Ailuropodamelanoleuca) as determined by PCR-TGGE profiling and clone library analysis[J]. Microb Ecol, 2007, 54(1): 194-202. DOI: 10.1007/s00248-007-9225-2
[10] Wu XJ, Chen ZH, Wang F. Application of PCR amplification ofHp16S rDNA fragment in the diagnose ofHpinfection[J]. J Mod Lab Med, 2010, 25(5): 76-78. DOI: 10.3969/i.issn.1671-7414.2010.05.028 (in Chinese)
吳曉娟, 陳崢宏, 王菲. PCR擴(kuò)增16S rDNA 在幽門螺桿菌感染診斷中的運(yùn)用[J].現(xiàn)代檢驗(yàn)醫(yī)學(xué)雜志, 2010, 25(5):76-78.
[11] Kohlmann R, Gatermann SG. Analysis and presentation of cumulative antimicrobial susceptibility test data— The influence of different parameters in a routine clinical microbiology laboratory[J] . PLoS One, 2016, 11(1): e0147965. DOI: 10.1371/journal.pone.0147965
[12] Amieva MR, El-Omar EM. Host-bacterial interactions inHelicobacterpyloriinfection[J]. Gastroenterology, 2008, 134(1): 306-323. DOI: 10.1053/j.gastro.2007.11.009
[13] Wu WM, Yang YS, Peng LH. Microbiota in the stomach: New insights[J]. J Dig Dis, 2014, 15(2): 54-61. DOI: 10.1111/1751-2980.12116
[14] Nardone G, Compare D. The human gastric microbiota: Is it time to rethink the pathogenesis of stomach diseases[J]. United European Gastroenterol J, 2015, 3(3): 255-260. DOI: 10.1177/2050640614566846
[15] Malnick SD, Melzer E, Attali M, et al.Helicobacterpylori: Friend or foe[J]. World J Gastroenterol, 2014, 20(27): 8979-8985. DOI: 10.3748/wjg.v20.i27.8979[16] Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, et al. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer[J]. Sci Rep, 2014, 4: 4202. DOI: 10.1038/srep04202
[17] Hu Y, He LH, Xiao D, et al. Bacterial flora concurrent withHelicobacterpyloriin the stomach of patients with upper gastrointestinal diseases[J]. World J Gastroenterol, 2012, 18(11): 1257-1261. DOI:10.3748/wjg.v18.i11.1257
[18] Osaki T, Matsuki T, Asahara T, et al. Comparative analysis of gastric bacterial microbiota in Mongolian gerbils after long-term infection withHelicobacterpylori[J]. Microb Pathog, 2012, 53(1): 12-18.
[19] Abreu MT, Peek RM Jr. Gastrointestinal malignancy and the microbiome[J]. Gastroenterology, 2014, 146(6): 1534-1546. DOI: 10.1053/i.gastro.2014.01.001
[20] Shang H, Wang YS, Shen ZY. National clinical laboratory procedures[M]. 4th ed. Beijing: People's Medical Publishing House, 2015: 718-719. (in Chinese)
尚紅,王毓三,申子瑜.全國(guó)臨床檢驗(yàn)操作規(guī)程[M].4版.北京:人民衛(wèi)生出版社,2015 : 718-719.
Investigation of clinical significance ofPseudomonasputidaisolated from gastric biopsies
YIN Lin1,2, LIU Fang2, GUO Chang-cheng2, WANG Qiong2, YANG Jie3, PAN Ke4,PAN Chen3, XIONG Yan5, CHEN Ying-ting3, FANG Wen1, CHEN Zheng-hong2
(1.DepartmentofClinicalLaboratorySciences,GuizhouMedicalUniversity.Guiyang550004,China;2.DepartmentofMicrobiology,SchoolofBasicMedicalSciences,GuizhouMedicalUniversity,Guiyang520025,China;3.DepartmentofGastrointestinalMedicine,theFirstAffiliatedHospitalofGuizhouMedicalUniversity,Guiyang550004,China;4.DepartmentofGastrointestinalMedicine,thePeople'sHospitalofQiannanAutonomousPrefecture,Duyun558000,China;5.DepartmentofGastrointestinalMedicine,GuiyangChildren'sHospital,Guiyang550004,China)
In order to investigate the role ofPseudomonasputidainH.pylori-associated gastrointestinal diseases, 354H.pyloripositive cases determined by14C-urea breath test were underwent endoscopy forH.pyloriisolation and identification.H.pyloriand non-H.pyloriwere identified by colonial morphology, Gram's staining, urease test andH.pylorispecific 16S rRNA gene fragment PCR amplification. Non-H.pyloriwere then inoculated on nutrient agar plate under aerobic conditions at 37℃ for 18-24 hours. Single bacterial colony was used for rapid urease test. Simultaneously, total genomic DNA were extracted from gastric mucosal tissue andH.pylorispecific 16S rDNA was amplified by PCR for rapid diagnosis. Urease positive non-H.pyloriwas selected for genomic DNA extraction and then bacterial 16S rDNA was amplified by general primers and then determined by sequencing. Sequence comparison was carried out by the BLASTn program and the GenBank databases (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Single colony which was identified asPseudomonasputidaby sequence alignment was then picked for subculturing. Drug susceptibility of 7 alive strains were detected by K-B disk diffusion method and also identified by automatic bacteria identification instrument. The results of 16S rDNA sequencing showed that a total of 10 strains were identified asPseudomonasputidafrom 354 cases. All of them are Gram's negative bacteria with urease activity. In these ten cases, 6 wereH.pylori-positive determined byH.pylorispecific PCR amplification, and 4 cases wereH.pylori-negative. All the seven alive strains ofPseudomonasputidawere susceptible to levofloxacin, 1 was susceptible to tetracycline, 5 were resistant to amoxicillin, 6 were resistant to clarithromycin and 7 were resistant to both metronidazole and Ampicillin. In conclusion,Pseudomonasputidawhich were urease-positive and resistant to antibiotic inH.pylorieradication can be isolated from diseased gastric mucosal tissue bacteria. These strains may cause false positive in clinical14C-urese breath test, and influenceH.pylori-associated gastrointestinal diseases progression.
Pseudomonasputida; culture; urease; 16S rRNA; drug resistance
Chen Zheng-hong, Email: chenzhenghong@gmc.edu.cn
10.3969/j.issn.1002-2694.2016.012.011
國(guó)家自然科學(xué)基金資助項(xiàng)目(No.81460314);貴陽(yáng)市衛(wèi)生和計(jì)劃生育委員會(huì)科學(xué)技術(shù)計(jì)劃項(xiàng)目([2014]筑衛(wèi)計(jì)科技合同字第018號(hào))聯(lián)合資助
陳崢宏,Email:chenzhenghong@gmc.edu.cn
1.貴州醫(yī)科大學(xué)醫(yī)學(xué)檢驗(yàn)學(xué)院臨床生化教研室,貴陽(yáng) 550004; 2.貴州醫(yī)科大學(xué)基礎(chǔ)醫(yī)學(xué)院微生物學(xué)教研室,貴陽(yáng) 550025; 3.貴州醫(yī)科大學(xué)附屬醫(yī)院消化內(nèi)科,貴陽(yáng) 550004; 4.黔南布依族苗族自治州人民醫(yī)院消化內(nèi)科,都勻 558000; 5.貴陽(yáng)市兒童醫(yī)院消化內(nèi)科,貴陽(yáng) 550000
R378
A
1002-2694(2016)12-1102-06
2016-05-14;
2016-09-14
Supported by the National Natural Science Foundation of China (No. 81460314) and the Guiyang Municipal Health and Family Planning Commission, Science and Technology Project, 2014(No. 018)
中國(guó)人獸共患病學(xué)報(bào)2016年12期